Calendars

Landec Corporation Provides Update on Curation Foods Transformation and Announces Preliminary Fiscal 2020 Fourth Quarter Results

Retrieved on: 
Monday, June 29, 2020

Landec also announced its preliminary fiscal 2020 fourth quarter financial results.

Key Points: 
  • Landec also announced its preliminary fiscal 2020 fourth quarter financial results.
  • The Company drove significant operational improvements within the Curation Foods business throughout fiscal 2020, largely visible in the fiscal fourth quarter, and operational improvements are expected to continue in fiscal 2021.
  • The Company is providing preliminary, unaudited financial results for the fiscal 2020 fourth quarter, ended May 31, 2020.
  • The Company currently expects to report its actual results for the fiscal 2020 fourth quarter and full fiscal year by early August.

Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis

Retrieved on: 
Monday, June 29, 2020

During the past three months, our very experienced clinical development team has successfully maintained open lines of communication with our sites.

Key Points: 
  • During the past three months, our very experienced clinical development team has successfully maintained open lines of communication with our sites.
  • Immunovant expects to report results from ASCEND MG, a Phase 2a trial of IMVT-1401 in MG, in late calendar Q3 or early calendar Q4.
  • Financial Highlights for Fiscal Fourth Quarter ended March 31, 2020 and Fiscal Year ended March 31, 2020:
    Cash Position: Cash balances as of March 31, 2020 and March 31, 2019 were $100.6 million and $7.0 million, respectively.
  • For the year ended March 31, 2020, net loss was $66.4 million compared to $28.6 million for the year ended March 31, 2019.

Aethlon Medical Announces Fiscal Year Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, June 25, 2020

SAN DIEGO, June 25, 2020 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.

Key Points: 
  • SAN DIEGO, June 25, 2020 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.
  • In other news, the Company announced that Thomas L. Taccini has joined the Aethlon management team as Vice President, Manufacturing and Product Development.
  • Operating expenses for the fiscal year ended March 31, 2020 were approximately $6.58 million, compared to $6.23 million for the fiscal year ended March 31, 2019.
  • The Company will hold a conference call today, Thursday, June 25, 2020 at 4:30 p.m. Eastern Time to review financial results and recent corporate developments.

AeroGrow Reports Record FY 2020 Results and Announces Significant Developments

Retrieved on: 
Tuesday, June 23, 2020

For the 4th Quarter ended March 31, 2020, the Company recorded net revenue of $11.8 million, an increase of 29% over the same period in the prior year.

Key Points: 
  • For the 4th Quarter ended March 31, 2020, the Company recorded net revenue of $11.8 million, an increase of 29% over the same period in the prior year.
  • For the year ended March 31, 2020, the Company recorded total revenue of $39.2 million, an increase of 14% over the prior year.
  • Income from Operations for the full year period was $308K, up from $6K in the prior year.
  • I think the overall state of the business as we begin FY 2021 is at an all-time high.

Federal Agency Awards $3.2 Million to Community Organizations for MLK Day, 9/11 Day

Retrieved on: 
Tuesday, June 23, 2020

Awarded to 29 organizations across the country, these grants will support volunteer activities on the annual Martin Luther King, Jr. Day of Service and the September 11 National Day of Service and Remembrance.

Key Points: 
  • Awarded to 29 organizations across the country, these grants will support volunteer activities on the annual Martin Luther King, Jr. Day of Service and the September 11 National Day of Service and Remembrance.
  • The $3.2 million announced today includes 10 new grants and the continuation of funding for 19 organizations funded in the 2019 Days of Service Grant Competition.
  • "The organizations receiving funding today will provide opportunities for Americans to make a difference through days of service like MLK Day and 9/11 Day."
  • The Corporation for National and Community Service is the federal agency for volunteering, service, and civic engagement.

Delaware Town that Banned Nativity Scene from Annual Christmas Display Sued by Knights of Columbus

Retrieved on: 
Tuesday, June 23, 2020

The Knights of Columbus simply wants to continue a beloved tradition of this town, said Roger Byron, Senior Counsel for First Liberty Institute.

Key Points: 
  • The Knights of Columbus simply wants to continue a beloved tradition of this town, said Roger Byron, Senior Counsel for First Liberty Institute.
  • It is perfectly lawful to have a crche on public property, and blatantly unlawful to ban it.
  • For decades, a free-standing crche has been part of the Christmas holiday tradition in Rehoboth Beach.
  • The local Knights of Columbus council is continuing the tradition of the crche display, but beginning in 2018 city officials banned the crche from city property because it is religious.

Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020

Retrieved on: 
Monday, June 22, 2020

Specifically, we achieved organic year-over-year revenue growth of 27% and IXINITY contributed an additional $9.5 million for the fourth quarter of 2020.

Key Points: 
  • Specifically, we achieved organic year-over-year revenue growth of 27% and IXINITY contributed an additional $9.5 million for the fourth quarter of 2020.
  • Approximately 85% of IXINITY revenue for the quarter accrued to Medexus in March and as such, was highly accretive.
  • For the fiscal year ended March 31, 2020, total revenue was $74.4 million compared to revenue of $33.9 million for the fiscal year ended March 31, 2019.
  • Adjusted EBITDA* for the year-ended March 31, 2020 was $6.0 million compared to $2.4 million for the fiscal year ended March 31, 2019.

WWII Veterans Remembered: U-Haul Honors Pennsylvania's Thomas E. Dudley

Retrieved on: 
Monday, June 22, 2020

This signifies Victory over Japan and is observed Sept. 2 when the signing of surrender occurred, effectively ending WWII.

Key Points: 
  • This signifies Victory over Japan and is observed Sept. 2 when the signing of surrender occurred, effectively ending WWII.
  • This is accomplished through recruiting veterans and giving them hiring preference; direct assistance to veteran groups; participation and sponsorship of Memorial Day and Veterans Day parades; and supporting Pearl Harbor tributes .
  • Dudley was born in Highland Park on Dec. 21, 1923, to Joseph and Marie Dudley.
  • Dudley was awarded the American Campaign Medal, the Asiatic-Pacific Campaign Medal with two bronze stars, and the WWII Victory Medal.

After COVID-19: the University of Nottingham Ningbo China Experience

Retrieved on: 
Friday, June 19, 2020

We rapidly decided to delay the start of the new semester and go online for at least a month.

Key Points: 
  • We rapidly decided to delay the start of the new semester and go online for at least a month.
  • Now that we are teaching on campus again, what are the challenges we have been facing and that others can expect?
  • Obviously, those unable to travel or with risky routes were not obliged to return, and we continue to support them online.
  • Contingency plans have to include moving rapidly back to 100% online delivery in the event of a resurgence of COVID-19 in China.

Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

Retrieved on: 
Thursday, June 18, 2020

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.
  • The 2019 fiscal year and fourth quarter have been transformational for our company, said James Robinson, president and chief executive officer of Urovant Sciences.
  • As previously announced, Urovant will hold a conference call today, June 18, 2020 to discuss financial results from the fourth quarter and full year fiscal 2019 ended March 31, 2020.
  • Unless otherwise noted, the three months and fiscal year comparisons are to the prior fiscal year comparable period ended March 31, 2019.